Difference between revisions of "UMODL1-AS1"
| Line 16: | Line 16: | ||
===Ensembl ID=== | ===Ensembl ID=== | ||
ENSG00000184385 | ENSG00000184385 | ||
| − | |||
| − | |||
===Function=== | ===Function=== | ||
| − | UMODL1-AS1 is significantly associated with ER and triple negative status.<ref name="ref1" /> | + | UMODL1-AS1's upregulation can predict recurrence of breast cancer.<ref name="ref1" /> UMODL1-AS1 is significantly associated with ER and triple negative status.<ref name="ref1" /> |
==Labs working on this lncRNA== | ==Labs working on this lncRNA== | ||
* Cancer Institute, University of Mississippi Medical Center, Jackson, MS, USA. <ref name="ref1" /> | * Cancer Institute, University of Mississippi Medical Center, Jackson, MS, USA. <ref name="ref1" /> | ||
Revision as of 11:51, 7 January 2018
Contents
Annotated Information
Approved Symbol
UMODL1-AS1 （UMODL1 antisense RNA 1）
LncRNA signature for recurrence based on RNA expression[1]
Alterations of lncRNAs associated with ER, PR and HER-2[1]
Previous Symbols
C21orf128
Synonyms
FLJ33471
Chromosome
21q22.3
RefSeq ID
NR_027243
Disease
breast cancer
Ensembl ID
ENSG00000184385
Function
UMODL1-AS1's upregulation can predict recurrence of breast cancer.[1] UMODL1-AS1 is significantly associated with ER and triple negative status.[1]
Labs working on this lncRNA
- Cancer Institute, University of Mississippi Medical Center, Jackson, MS, USA. [1]
